DK1423376T3 - Bicyklisk forbindelse, fremstilling og anvendelse deraf - Google Patents

Bicyklisk forbindelse, fremstilling og anvendelse deraf

Info

Publication number
DK1423376T3
DK1423376T3 DK02762751.2T DK02762751T DK1423376T3 DK 1423376 T3 DK1423376 T3 DK 1423376T3 DK 02762751 T DK02762751 T DK 02762751T DK 1423376 T3 DK1423376 T3 DK 1423376T3
Authority
DK
Denmark
Prior art keywords
preparation
bicyclic compound
bicyclic
compound
Prior art date
Application number
DK02762751.2T
Other languages
English (en)
Inventor
Katsuji Aikawa
Yuji Iizawa
Mitsuru Shiraishi
Masanori Baba
Naoyuki Kanzaki
Masaki Seto
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Application granted granted Critical
Publication of DK1423376T3 publication Critical patent/DK1423376T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
DK02762751.2T 2001-08-08 2002-08-07 Bicyklisk forbindelse, fremstilling og anvendelse deraf DK1423376T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12
PCT/JP2002/008043 WO2003014105A1 (en) 2001-08-08 2002-08-07 Bicyclic compound, production and use as hiv inhibitors

Publications (1)

Publication Number Publication Date
DK1423376T3 true DK1423376T3 (da) 2010-06-28

Family

ID=26620186

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10150963.6T DK2206702T3 (da) 2001-08-08 2002-08-07 Bicyklisk forbindelse, fremstilling og anvendelse deraf
DK02762751.2T DK1423376T3 (da) 2001-08-08 2002-08-07 Bicyklisk forbindelse, fremstilling og anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10150963.6T DK2206702T3 (da) 2001-08-08 2002-08-07 Bicyklisk forbindelse, fremstilling og anvendelse deraf

Country Status (13)

Country Link
US (7) US7371772B2 (da)
EP (3) EP2206702B1 (da)
JP (4) JP4316203B2 (da)
AR (1) AR034985A1 (da)
AT (2) ATE539062T1 (da)
AU (1) AU2002328092A1 (da)
CA (2) CA2607992A1 (da)
DE (1) DE60235632D1 (da)
DK (2) DK2206702T3 (da)
ES (2) ES2339340T3 (da)
PE (1) PE20030329A1 (da)
PT (2) PT1423376E (da)
WO (1) WO2003014105A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030329A1 (es) * 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
EP1593681A4 (en) * 2003-02-07 2007-09-05 Takeda Pharmaceutical TRICYCLIC COMPOUND, PROCESS FOR THEIR PREPARATION AND USE
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
CA2560298A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
WO2005089714A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
WO2006059716A1 (ja) * 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
RU2011119533A (ru) * 2008-10-17 2012-11-27 Инваск Терапеутикс, Инк. Композиции и способы для лечения нарушений деятельности, связанных с ренин-ангиотензин-альдостероновой системой (раас)
WO2011066352A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
EP2552429A1 (en) 2010-04-02 2013-02-06 Phivco-1 LLC Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
HK1232147A1 (zh) 2014-03-21 2018-01-05 Tobira Therapeutics, Inc. 用於治疗纤维化的赛尼克韦罗
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
BR112017004708A2 (pt) 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
JP6716568B2 (ja) * 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
BR112017016388A2 (pt) 2015-02-10 2018-03-27 Tobira Therapeutics, Inc. cenicriviroc para o tratamento da fibrose
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
JP2019520427A (ja) * 2016-06-21 2019-07-18 トビラ セラピューティクス， インコーポレイテッド 精製されたセニクリビロク及びセニクリビロク製造のための精製された中間体
MX2019002057A (es) * 2016-08-31 2019-11-18 Tobira Therapeutics Inc Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
ES2906992T3 (es) 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
CA3051977A1 (en) 2017-02-24 2018-08-30 Genfit Pharmaceutical compositions for combination therapy
WO2019149089A1 (zh) 2018-02-02 2019-08-08 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
ES2995012T3 (en) * 2019-06-24 2025-02-05 Wuxi Life Fountain Biotech Co Ltd Heterocyclo alkyl compounds used as ccr2/ccr5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US12466817B2 (en) 2020-05-22 2025-11-11 Nicoya Therapeutics (Shanghai) Co., Ltd Pyridine derivative and application thereof
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
WO2024240025A1 (zh) * 2023-05-22 2024-11-28 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
AU9461898A (en) 1997-10-20 1999-05-10 Dainippon Pharmaceutical Co. Ltd. Stable drug composition
US6172061B1 (en) * 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6235771B1 (en) 1998-12-21 2001-05-22 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
WO2000061109A1 (fr) 1999-04-12 2000-10-19 Shionogi & Co., Ltd. Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
PE20030329A1 (es) * 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
JP2004123694A (ja) 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
WO2005089714A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
CA2560298A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
WO2006059716A1 (ja) * 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
EP2552429A1 (en) 2010-04-02 2013-02-06 Phivco-1 LLC Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
CN103402998B (zh) 2010-11-18 2017-09-26 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
WO2013000922A1 (en) 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Ccr2 antagonist peptides
CN105263498B (zh) 2013-05-15 2019-04-26 妥必徕疗治公司 赛尼克韦罗组合物及其制备和使用方法
HK1232147A1 (zh) 2014-03-21 2018-01-05 Tobira Therapeutics, Inc. 用於治疗纤维化的赛尼克韦罗
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
BR112017016388A2 (pt) 2015-02-10 2018-03-27 Tobira Therapeutics, Inc. cenicriviroc para o tratamento da fibrose

Also Published As

Publication number Publication date
US20120232028A1 (en) 2012-09-13
ES2339340T3 (es) 2010-05-19
DK2206702T3 (da) 2012-02-13
JP2013136629A (ja) 2013-07-11
US8183273B2 (en) 2012-05-22
JP5275148B2 (ja) 2013-08-28
EP1889839B1 (en) 2013-11-06
AR034985A1 (es) 2004-03-24
HK1142886A1 (en) 2010-12-17
PT2206702E (pt) 2012-02-03
JP4316203B2 (ja) 2009-08-19
CA2459172A1 (en) 2003-02-20
EP2206702B1 (en) 2011-12-28
ES2376855T3 (es) 2012-03-20
US20160008326A1 (en) 2016-01-14
AU2002328092A1 (en) 2003-02-24
US20090030032A1 (en) 2009-01-29
EP1889839A1 (en) 2008-02-20
US7371772B2 (en) 2008-05-13
US20190038604A1 (en) 2019-02-07
PT1423376E (pt) 2010-04-12
US10045968B2 (en) 2018-08-14
US20040259876A1 (en) 2004-12-23
WO2003014105A1 (en) 2003-02-20
US8362058B2 (en) 2013-01-29
JP2009209154A (ja) 2009-09-17
PE20030329A1 (es) 2003-05-12
ATE460406T1 (de) 2010-03-15
EP1423376B1 (en) 2010-03-10
US20200297700A1 (en) 2020-09-24
CA2459172C (en) 2011-07-05
WO2003014105A9 (en) 2003-11-20
JP2007084578A (ja) 2007-04-05
JP2003335776A (ja) 2003-11-28
US8741943B2 (en) 2014-06-03
EP2206702A1 (en) 2010-07-14
EP1423376A1 (en) 2004-06-02
CA2607992A1 (en) 2003-02-20
US20080161287A1 (en) 2008-07-03
DE60235632D1 (de) 2010-04-22
JP4358851B2 (ja) 2009-11-04
ATE539062T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
DK2206702T3 (da) Bicyklisk forbindelse, fremstilling og anvendelse deraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
EP1417988A4 (en) RESPIRATORY EQUIPMENT
DE60222056D1 (de) Hebestuhl
DK1421841T3 (da) Mejetærsker
ITTO20010940A0 (it) ,,sedia,,
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
DE50208287D1 (de) Bicyclische n-arylamide
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DE60210848D1 (de) Verbinder
DE50202174D1 (de) Schliesszylinder
DE50200466D1 (de) Symmetrierübertrager
DE60221366D1 (de) Verbinder
DE50203644D1 (de) Abseilvorrichtung
DE60233695D1 (de) Verbinder
FR2821754B1 (fr) Descenceur autobloquant
DE50108179D1 (de) Verbinder
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen
DE60229395D1 (de) Altung
ATA2892002A (de) Beschlag
SE0202516D0 (sv) Novel compounds, their use, and preparation
NO20042856L (no) Substituerte 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner og anvendelse av samme
SE0101037D0 (sv) Novel use